An investigation for current long-term investors in shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) over potential wrongdoing by certain officers and directors of Progenics Pharmaceuticals was announced and current long-term NASDAQ:PGNX ...

TARRYTOWN, May 17, 2013 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) today announced that it has been selected for addition to the NASDAQ Biotechnology Index effective prior to market open on Monday, May ...

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") (NasdaqGS: PGNX) for ...

Progenics Pharmaceuticals, Inc. discovers and develops innovative medicines for oncology, with a pipeline that includes product candidates in preclinical through late-stage development.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rose 19.64% to $6.58 and ranged between $6.00 and $7.23 after its price target was raised to $17 from $11 at Lazard Capital.

TARRYTOWN, N.Y., April 24, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) chief executive officer Mark R. Baker will make a presentation on Tuesday, April 30 at 3:00 PM EDT at Needham & Company's 12th Annual ...

Progenics Pharmaceuticals, Inc.(NASDAQ:PGNX) shares increased 10.70% to $4.76. The company on May 10 announced its results of operations for the quarter ended March 31.

Progenics in January acquired Molecular Insight Pharmaceuticals Inc., a clinical-stage private biotechnology company headquartered in Cambridge, Mass., in an all-stock transaction. The Massachusetts company has a development pipeline of targeted ...

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) is a biopharmaceutical company focused on the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening ...

The following eleven securities will be added to the Index: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) ; Albany Molecular Research, Inc. (NASDAQ:AMRI) ; Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) ; Clovis Oncology, Inc. (NASDAQ:CLVS) ; Furiex ... Inc ...